Immuno Oncology Drugs Market Booming Worldwide with Latest Trend and Future Scope by 2031

Immuno oncology drugs market is expected to grow at a significant CAGR during the forecast period.  Cancer is the second biggest cause of mortality globally, following cardiovascular disease. According to research published by the World Health Organization (WHO) in 2018, cancer is responsible for 8.3 million mortalities each year, with 70% of new cancer cases likely to be recorded in the next 20 years. Further, Africa, Asia, Central and South America account for more than 60% of new cancer cases and 70% of cancer mortalities globally. The rise in the prevalence of cancer and the popularity of advanced therapies (biological and targeted pharmacological therapies) are driving the growth of the global immuno oncology drugs market. Furthermore, increased cancer awareness and early cancer screening contribute to the growth of the market. However, the high costs associated with new medication development, as well as the risk of failure and side effects associated with cancer treatment therapies, are hampering the growth of the market.

Based on the therapeutic application, the market is segmented into breast cancer, melanoma, lung cancer, blood cancers, renal cell carcinoma, prostate cancer, bladder cancer, and other cancers. Among these, the breast cancer segment is expected to hold a major share in the market during the forecast period, owing to an increase in the number of people affected by the disease and the availability of early detection. On the other hand, the demand for immune-oncology drugs for lung cancer treatment is expected to grow at the fastest rate during the forecast period, owing to higher incidence, an increase in the geriatric population, changes in people's lifestyles, increase in tobacco smoking, passive smoking, which could lead to lung cancer.

To Request a Sample of our Report on Immuno Oncology Drugs Market:  https://www.omrglobal.com/request-sample/immuno-oncology-drugs-market

Market Coverage

The market number available for - 2021-2029
Base year- 2020
Forecast period- 2023-2029
Segment Covered
Regions Covered- Globally

Competitive Landscape: Amgen Inc., AbbVie Inc., Astellas Pharma Inc., AstraZeneca PLC, Bristol-Myers Squibb Co., and Pfizer Inc.

Global Immuno Oncology Drugs Market Report by Segment

By Type

Monoclonal Antibodies
Immune Checkpoint Inhibitors
Cancer Vaccines
Immune System Modulators
Others

By Therapeutic Application

Breast Cancer
Melanoma
Lung Cancer
Blood Cancers
Renal Cell Carcinoma
Prostate Cancer
Bladder Cancer
Other Cancers

By End-User 

Hospitals
Clinics
Ambulatory Surgical Centers

A full Report of Immuno Oncology Drugs Market is Available @  https://www.omrglobal.com/industry-reports/immuno-oncology-drugs-market

Immuno Oncology Drugs Market by Region

North America

United States
Canada

Europe

UK
Germany
Spain
France
Italy
Rest of Europe

Asia-Pacific

India
China
Japan
South Korea
Rest of APAC

Rest of the World

Reasons to buy from us -                                                                                                                           

We cover more than 15 major industries, further segmented into more than 90 sectors.
More than 120 countries are for analysis.
Over 100+ paid data sources mined for investigation.
Our expert research analysts answer all your questions before and after purchasing your report.

For More Customized Data, Request for Report Customization @ https://www.omrglobal.com/report-customization/immuno-oncology-drugs-market

Media Contact:

Company Name: Orion Market Research

Contact Person: Mr. Anurag Tiwari

Email: info@omrglobal.com

Contact no:  +91 7803040404

About Orion Market Research 

Orion Market Research (OMR) is a market research and consulting company known for its crisp and concise reports. The company is equipped with an experienced team of analysts and consultants. OMR offers quality syndicated research reports, customized research reports, consulting and other research-based services.

This release was published on openPR.